
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is in a strong position for future growth due to its pipeline of selective oral immunology therapies, targeting chronic inflammatory and autoimmune diseases such as ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. With potential disease modification in RMS, as well as neuroprotection and enhanced neuronal survival, Immunic's vidofludimus calcium has the potential to address key gaps in current treatment approaches. Their recent financing deal of $200M in upfront gross proceeds also provides a strong financial foundation and supports their plans for NDA submission and potential approval in the coming years.
Bears say
Immunic is a clinical-stage biopharmaceutical company with a focus on developing oral immunology therapies for chronic inflammatory and autoimmune diseases. Its current pipeline includes three small molecule products targeting various diseases, with Phase 3 data expected by the end of 2026. However, with previous trials in progressive multiple sclerosis showing only modest improvement, and a lack of differentiation in the market for relapsing multiple sclerosis, combined with the potential risks of clinical and commercial development, there may be limited opportunities for Immunic to achieve success and long-term growth. As of now, it may be prudent for investors to be cautious about investing in this stock.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares